At Amrita TBI, we are committed to nurturing innovations that solve real-world problems. One such remarkable journey is that of CURO Biosciences Private Limited, known by their brand name ErlySign, which has just secured its first-ever external funding — ₹16 crore in a pre-Series A round — to advance its saliva-based oral cancer detection technology.
What makes this milestone notable is that it began with a NIDHI-PRAYAS grant from Amrita TBI — their very first funding support.
In 2023, Shubendra Singh, founder of CURO Biosciences, received the NIDHI-PRAYAS grant through Amrita TBI to build a prototype for an oral cancer detection device. With no prior funding, Amrita TBI became the first incubator to believe in their vision.
The team developed a non-invasive, saliva-based diagnostic device for early detection of oral cancer. The device is now undergoing clinical trials, with the goal of making cancer detection faster, easier, and accessible .
Fast forward to today, CURO Biosciences has successfully raised ₹16 crore in a pre-Series A round — a huge leap for a startup that began its journey with a prototype and a vision.
This funding will accelerate clinical validation, regulatory approvals, and market readiness for their diagnostic platform — bringing them closer to real-world impact.
" We are grateful to Amrita TBI for awarding us the NIDHI PRAYAS grant, which was the very first grant we received. This support came at a crucial time and played a significant role in shaping our product development journey. Amrita TBI has been the first and the only incubator we have been associated with since 2023, providing us with invaluable guidance and a nurturing ecosystem.
We take this opportunity to thank Amrita TBI for believing in our idea and providing us the funds. Their belief in us gave us the confidence to move forward, refine our vision, and take the necessary steps toward building an impactful product. Today, we are proud to share that we have successfully raised our Pre series A in private equity funding. We are excited about the future ahead. Thank you for being a part of our journey. "
This is a shining example of how early-stage support — through programs like NIDHI-PRAYAS — can catalyze groundbreaking healthcare innovation. CURO Biosciences' journey reflects the spirit of Amrita TBI: empowering entrepreneurs, enabling breakthrough technologies, and creating real impact.
We are proud to have been a part of CURO’s journey from the very beginning, and we look forward to seeing their continued success as they reshape cancer diagnostics in India and beyond.
CURO Biosciences secures ₹16 crore for advancing saliva-based cancer detection tech